Smith & Nephew PLC (SN.)

Industry Medical Devices
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell

0.00p

Buy

1,090.00p

arrow-up2.00p (+0.19%)

Smith & Nephew PLC designs, manufactures, and markets orthopedic devices and wound-care solutions. Its products include knee replacements, hip implants, nails, fixation devices, arthroscopy tools and others.
Prices updated at 02 Jun 2025, 17:30 BST
| Prices minimum 15 mins delay
|
Prices in GBX
FTSE All-Share
arrow-up0.02%
LSE
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Medical Devices
Chairman
Mr. Rupert C Soames OBE
CEO
Mr. Deepak S. Nath
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
17,349
Head office
Hatters Lane
Watford
United Kingdom
WD18 8YE
mobile
+44 1923477100
letter
investorrelations.global@smith-nephew.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Ms. Angie Risley
Non-Executive Director, Senior Independent non-executive director
---0.13m-
Mr. Rupert C Soames OBE
Non-Executive Director, Chairman
---0.58m-
Mr. Marc E. Owen
Non-Executive Director
---0.20m-
Mr. Simon Jonathan Lowth
Non-Executive Director
-----
Mr. Jeremy Kim Maiden
Non-Executive Director
---0.12m-
Ms. Joanna Christine Hallas
Non-Executive Director
-----
Dr. Katarzyna Mazur-Hofsaess, PhD
Non-Executive Director
-----
Ms. Sybella Jane Stanley
Non-Executive Director
-----
Dr. John Ma
Non-Executive Director
-----
Mr. John Terence Rogers
Executive Director, Chief Financial Officer
-----
Mr. Deepak S. Nath
Executive Director, Chief Executive Officer
-----

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
Principal Global Investors LLC39,991,91022.103675946771-31 May 20254.57
Harris Associates L.P.25,734,8844.04623-6557650-31 May 20252.94
Vanguard Group Inc25,314,7570.6938184768-31 May 20252.89
Massachusetts Financial Services Company20,882,7118.5020161308-31 May 20252.39
PGI CIT International Equity Fund18,688,8402.19014221905013.47345731 May 20252.14

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
28 May 2025DMr. Deepak S. Nath1065.6736,840269,3510.03Dividend Reinvestment Plan(DRIP)
20 May 2025SaleMr. Deepak S. Nath1087.54374,950265,8940.03-
20 May 2025Transfer inMr. Deepak S. Nath--300,3710.03As advised by the company
01 May 2025PurchaseMr. Jeremy Kim Maiden1070.0019,8493,1480.00-
26 Mar 2025PurchaseMs. Sybella Jane Stanley1101.0041,9483,8100.00-
19 Dec 2024PurchaseMr. John Terence Rogers971.96699,03071,9200.01-
06 Dec 2024PurchaseMs. Joanna Christine Hallas980.285,2446,1900.00Fees
05 Dec 2024Sale of OptionMr. Deepak S. Nath981.20333,932215,4360.02-
05 Dec 2024Exercise of OptionMr. Deepak S. Nath--249,4690.03-
11 Nov 2024PurchaseMr. Rupert C Soames OBE935.9050,01419,7540.00-
08 Nov 2024DMr. Deepak S. Nath923.4017,766166,4120.02Dividend Reinvestment Plan(DRIP)
01 Nov 2024PurchaseDr. John Ma25.648,1261,8170.00Fees
23 Sep 2024PurchaseMr. Marc E. Owen15.425,36717,2060.00Fees
17 Sep 2024PurchaseDr. Katarzyna Mazur-Hofsaess1184.255,4711,8300.00Fees
16 Sep 2024PurchaseMr. Simon Jonathan Lowth1189.933,5703000.00-
16 Sep 2024PurchaseMs. Angie Risley1189.933,7135,9780.00-
16 Sep 2024PurchaseMr. Robert J. White15.748,1238,3760.00ADRs
11 Sep 2024PurchaseMr. Jeremy Kim Maiden1208.173,5401,2930.00Fees
06 Aug 2024PurchaseMr. Rupert C Soames OBE1166.0262,61514,4100.00As advised by the company
05 Jul 2024PurchaseMr. Deepak S. Nath10.539,803164,4880.02ADRs
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.